On April 6, 2020 RemeGen, a Yantai biotech, reported that it has closed a $100 million funding co-led by Lilly Asia Ventures and Lake Bleu Capital (Press release, RemeGen, APR 6, 2020, View Source [SID1234556160]). Founded in 2008, RemeGen is developing a pipeline of over ten novel biologics for autoimmune, cancer and ophthalmology diseases . The proceeds will advance commercialization of the company’s two lead molecules. RC18 (telitacicept) is a fusion protein with a China NDA filed for systemic lupus erythematosus (SLE). It is also currently in Phase II or Phase III trials for six other autoimmune diseases. RC48, a HER2 ADC, is currently in pivotal clinical trials for gastric and urothelial cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!